To systematically evaluate the epidemiological association between serum insulin-like growth factor-1 (IGF-I) levels and the risk of prostate cancer, in order to provide evidence-based support for risk stratification and early prevention of prostate cancer. This evidence concerns the gene IGF1 and prostate carcinoma.